|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab : A pilot study
| Title: | Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab : A pilot study |
| Authors: | Noguchi, Atsushi Browse this author | | Yasuda, Shinsuke Browse this author →KAKEN DB | | Hisada, Ryo Browse this author | | Kato, Masaru Browse this author →KAKEN DB | | Oku, Kenji Browse this author →KAKEN DB | | Bohgaki, Toshiyuki Browse this author →KAKEN DB | | Suzuki, Miho Browse this author | | Matsumoto, Yoshihiro Browse this author | | Atsumi, Tatsuya Browse this author →KAKEN DB |
| Keywords: | Anti-cyclic citrullinated peptide antibody | | B-cell subpopulation | | rheumatoid arthritis | | tocilizumab |
| Issue Date: | 3-Mar-2020 |
| Publisher: | Taylor & Francis |
| Journal Title: | Modern rheumatology |
| Volume: | 30 |
| Issue: | 2 |
| Start Page: | 276 |
| End Page: | 281 |
| Publisher DOI: | 10.1080/14397595.2019.1583784 |
| Abstract: | Objectives: To analyze the effects of tocilizumab on peripheral B-cell subpopulation and its ability to produce anti-cyclic citrullinated peptide (CCP) antibody in patients with rheumatoid arthritis (RA). Methods: Thirteen consecutive RA patients initiated with tocilizumab were enrolled in our prospective study. Anti-CCP antibody titers and clinical parameters were evaluated during treatment. Peripheral blood B-cell subsets were analyzed using flow cytometry according to the Human Immunology Project. Results: Disease activity was significantly improved and anti-CCP antibody titers significantly decreased at week 24 compared to baseline. The percentages of post-switch memory B cells in CD19+ cells transiently increased at week 12, but there was no significant difference in any of the investigated B-cell subpopulations at week 24 compared to baseline. The ratios of post-switch memory to naive B cells (post-switch/naive) correlated negatively with anti-CCP antibody titers regardless of the time-points. Conclusion: Our study indicated that tocilizumab has a potential to reduce anti-CCP antibody production presumably by affecting post-switch/naive ratio, and that anti-CCP antibody titers reflect B-cell distribution/subpopulation. As anti-CCP antibodies are produced in lymph nodes or ectopic lymphoid structures in synovial tissues, not in circulation, transient increment of post-switch memory B cells after tocilizumab treatment may reflect the altered balance of B-cell distribution between circulation and arthritic joints, resulting in suppressed production of anti-CCP antibody in situ. |
| Rights: | This is an Accepted Manuscript of an article published by Taylor & Francis in Modern rheumatology on 3 Mar 2020, available online: http://www.tandfonline.com/10.1080/14397595.2019.1583784. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/80540 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 渥美 達也
|
